Currently, we are also seeing that the Fibonacci golden ratio is also coming near 24,400 level. So, closing once Nifty gets above that level on the spot basis, after that we will witness some stable buying in the market.
Pankaj Pandey suggests that while Q4 earnings were subdued, FY26 looks promising, particularly for the commodity sector. Cement and steel are highlighted as potential outperformers due to expected earnings improvements and price increases. He also notes the positive impact of declining crude oil prices on OMCs and other user industries, emphasizing the structural benefits for India.
Nifty has surged 10% from its April low, reaching 24,461, prompting experts to advise caution on lumpsum investments due to expected volatility. SIPs remain the preferred route for long-term investors, while staggered allocations via STPs are suggested for those with funds. Auto, international, and tech sector funds have shown double-digit gains since April, driven by strong earnings and global tailwinds.
Glenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated RRMM patients. The tri-specific antibody showed high response rates and a favorable safety profile in early trials. Complete results will be presented at ASCO 2025. The stock rose 2.2% on Monday, with analysts maintaining a 'Buy' rating.
DCM Shriram's shares surged by 10.5% following a robust Q4 FY25 performance, with net profit soaring 51.9% to Rs 178.9 crore. Revenue climbed 19.9% to Rs 2,876.7 crore, driven by strong segment results and improved EBITDA margins of 14.1%. The board has proposed a final dividend of Rs 3.40 per share.
From the tactical success of the Elever FactorShields Fund, which delivered 20% returns in FY25, to sharp views on the US-led macro shifts and sector rotation strategies, Aggarwal outlines how investors can align portfolios for stability and long-term alpha. Edited Excerpts
